IMM-0306

DB19309InvestigationalProtein Based Therapies

IMM-0306 (bispecific antibody-trap selectively targeting cd47 and cd20) is under investigation in clinical trial NCT05805943 (Study of IMM0306 in Patients With Relapsed or Refractory Cd20-positive B-cell Non-hodgkin's Lymphoma).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD20 and Leukocyte surface antigen CD47
Curator reviewed
Also known as: IMM0306 (BISPECIFIC ANTIBODY-TRAP SELECTIVELY TARGETING CD47 AND CD20)
Code names: IMM-0306

Resolves to

Compound

UNIIHFR7WU5YK7

Targets

P11836MS4A1Q08722CD47

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with IMM-0306, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account